1 February 2023 in Radiology
Dilated vasculature in the arterial phase of dynamic CT and lower relative enhancement ratio in the hepatobiliary phase of gadoxetic acid–enhanced MRI were associated with P53-mutated hepatocellula... Background Imaging markers of hepatocellular carcinoma (HCC) on the basis of molecular classification are important for predicting malignancy grade and prognosis. P53-mutated HCC is a major aggress...
1 September 2019 in Biochemical and Biophysical Research Communications
20 November 2015 in Clinical and Experimental Nephrology
15 November 2012 in British Journal of Haematology
The prevalence, clinical associations and pathogenic role of newly identified autoantibodies to the erythropoietin receptor (EPOR) in patients with anaemia were investigated. Sera from 203 patients with immune‐related or chronic kidney diseases were screened for anti‐EPOR antibodies by enzyme‐linked immunosorbent assay, and antibody specificity was evaluated by immunoprecipitating EPOR from AS‐E2 cells using purified immunoglobulin (Ig) fractions. In addition, the pathogenic role of anti‐EPOR antibodies was determined by examining their inhibitory effects on AS‐E2 cell proliferation. Clinical findings were compared between patients with and without anti‐EPOR antibodies, in all patients and those with systemic lupus erythematosus (SLE). Serum anti‐EPOR antibodies were detected in 52 patients. Purified IgG or IgM fractions from anti‐EPOR antibody‐positive sera immunoprecipitated EPOR and inhibited the EPO‐dependent proliferation of AS‐E2 cells in a dose‐dependent manner. Anti‐EPOR antibodies were associated with low haemoglobin concentrations and reticulocytopenia in all patients enrolled and those with SLE. Further, there was a negative correlation between the levels of anti‐EPOR antibodies and the number of bone marrow erythroblasts in patients who underwent bone marrow examinations. These findings suggest that EPOR autoantibodies are present in a subset of patients with anaemia and that impaired erythropoiesis can be mediated by anti‐EPOR antibodies, which functionally neutralize EPO activity.
2 December 2010 in International Journal of Cancer
The identification of genes involved in tumor growth is crucial for the development of inventive anticancer treatments. Here, we have cloned a 17‐kDa secretory protein encoded by c19orf10 from hepatocellular carcinoma (HCC) serial analysis of gene expression libraries. Gene expression analysis indicated that c19orf10 was overexpressed in approximately two‐thirds of HCC tissues compared to the adjacent noncancerous liver tissues, and its expression was significantly positively correlated with that of alpha‐fetoprotein (AFP). Overexpression of c19orf10 enhanced cell proliferation of AFP‐negative HLE cells, whereas knockdown of c19orf10 inhibited cell proliferation of AFP‐positive Hep3B and HuH7 cells along with G1 cell cycle arrest. Supplementation of recombinant c19orf10 protein in culture media enhanced cell proliferation in HLE cells, and this effect was abolished by the addition of antibodies developed against c19orf10. Intriguingly, c19orf10 could regulate cell proliferation through the activation of Akt/mitogen‐activated protein kinase pathways. Taken together, these data suggest that c19orf10 might be one of the growth factors and potential molecular targets activated in HCC.
1 November 2010 in Journal of Clinical Microbiology
Although PCR-basedin situhybridization (PCR-ISH) can be used to determine the distribution and localization of pathogens in tissues, this approach is hampered by its low specificity. Therefore, we used a highly specific and sensitive PCR-ISH method to reveal the lobular distribution and intracellular localization of hepatitis B virus (HBV) and HCV in chronic liver disease and to clarify the state of persistent HBV and HCV infection in the liver. HBV genomic DNA was detected in almost all hepatocytes, whereas HBV RNA or protein was differentially distributed only in a subset of the HBV DNA-positive region. Further, HCV genomic RNA was detected in almost all hepatocytes and was localized to the cytoplasm. HCV RNA was also detected in the epithelium of the large bile duct but not in endothelial cells, portal tracts, or sinusoidal lymphocytes. In patients with HBV and HCV coinfection, HCV RNA was localized to the noncancerous tissue, whereas HBV DNA was found only in the cancerous tissue. Using this novel PCR-ISH method, we could visualize the staining pattern of HBV and HCV in liver sections, and we obtained results consistent with those of real-time detection (RTD)-PCR analysis. In conclusion, almost all hepatocytes are infected with HBV or HCV in chronic liver disease; this finding implies that the viruses spreads throughout the liver in the chronic stage.